Alto Neuroscience, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Emerging growth company
State of Incorporation
DE
Business Address
650 CASTRO STREET, SUITE 450, MOUNTAIN VIEW, CA, 94041
Mailing Address
650 CASTRO STREET, SUITE 450, MOUNTAIN VIEW, CA, 94041
Phone
773-255-5012
Fiscal Year End
1231
EIN
834210124
Financial Overview
FY2025
-$61.43M
Net Income
$33.55M
Total Liabilities
$151.46M
Stockholders' Equity
$-2.19
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | April 1, 2026 | View on SEC |
| DEF 14A Definitive proxy statement | March 26, 2026 | View on SEC |
| 10-K Annual financial report | March 16, 2026 | View on SEC |
| 8-K Current report of material events | March 16, 2026 | View on SEC |
| 8-K Current report of material events | March 16, 2026 | View on SEC |
| 4 Insider stock transaction report | March 3, 2026 | View on SEC |
| 4 Insider stock transaction report | March 3, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 18, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 17, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 17, 2026 | View on SEC |
Annual Reports
10-K
March 16, 2026
- Pioneering "precision psychiatry" approach using biomarkers to develop treatments for neuropsychiatric disorders.
- Robust pipeline with Alto100 in Phase 2b (MDD, PTSD) and Alto300 in Phase 2 (MDD), alongside earlier-stage programs.
Material Events
8-K
Other
March 16, 2026
High Impact
- Projected cash runway into 2028, indicating financial stability.
- ALTO-207 received FDA Fast Track designation, accelerating its development.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.